Product Description
Deuruxolitinib (CTP-543) is a deuterium-modified analogue of the JAK inhibitorÊruxolitinib. It is an oral inhibitor that inhibits JAK1/2. The chemical structure, and its use in hair loss disorders are claimed in patent WO2017192905A1 (Sourced from: https://www.guidetoimmunopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=11410)
Mechanisms of Action: JAK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Breakthrough Therapy - Alopecia|Alopecia Areata *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Concert
Company Location: LEXINGTON MA 02421
Company CEO: Roger D. Tung
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, France, Germany, Hungary, Poland, Spain, United States
Active Clinical Trial Count: 14
Highest Development Phases
Phase 3: Alopecia Areata
Phase 1: Healthy Volunteers|Kidney Diseases|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CP543.5001 | P3 |
Active, not recruiting |
Alopecia Areata |
2025-05-01 |
|
2021-002365-18 | P3 |
Active, not recruiting |
Alopecia Areata |
2024-09-06 |
|
CP543.5002 | P3 |
Completed |
Alopecia Areata |
2024-07-18 |
|
CP543.2004 | P2 |
Completed |
Alopecia Areata |
2023-05-15 |